Barclays lifts Bath & Body Works stock rating, sets $43 target

Published 24/02/2025, 10:20
Barclays lifts Bath & Body Works stock rating, sets $43 target

On Monday, Barclays (LON:BARC) upgraded Bath & Body Works Inc. (NYSE:BBWI) stock rating from Underweight to Equalweight, setting a price target of $43.00. The revision by Barclays analysts comes as they observe a reduced risk to merchandise margins and note an improvement in the company’s promotional strategy. The analysts have detected a positive trend in the first quarter to date of 2025 (1QTD25), with fewer promotions needed to drive business, indicating a shift to better performance.

The upgrade is further supported by the successful introduction of new product categories, which has significantly reduced clearance inventory levels. According to the analysts, this development, along with Bath & Body Works’ merchandise margins still trailing behind historical averages, suggests a potential for margin recovery alongside positive sales projections for 2025.

Barclays highlights several factors that contribute to the more favorable outlook for Bath & Body Works. These include the company’s attractive next twelve months (NTM) price-to-earnings (PE) ratio of 11x, the anticipated reduction of debt leading to lower interest expenses, and the possibility of increased share repurchases. These elements underpin the decision to upgrade the stock’s rating.

Despite the upgrade, Barclays remains cautious due to the uncertain consumer macro environment and the fact that a significant portion of the first quarter is yet to unfold. The firm emphasizes the need for additional data points to confirm a long-term acceleration in market share for Bath & Body Works. The analysts will continue to monitor the company’s performance for signs that substantiate a sustained improvement in its market position.

In other recent news, Bath & Body Works has been the subject of several notable developments. The company is expected to surpass fourth-quarter earnings per share expectations, with Citi projecting a result of $2.07, slightly above the consensus estimate of $2.04. This anticipated performance is attributed to stronger sales and effective marketing strategies. Meanwhile, JPMorgan has upgraded Bath & Body Works’ stock rating from Neutral to Overweight, raising the price target to $47.00, citing a "fundamental inflection" in revenue and earnings.

Additionally, Bath & Body Works announced a change in its executive team, with Chief Human Resources Officer Deon Riley set to depart by early March 2025. The company has also disclosed plans to redeem all remaining 9.375% Senior Notes due 2025 as part of its debt management strategy. Goldman Sachs has reiterated a Buy rating on the company’s stock, maintaining a price target of $52.00, based on expectations of stabilized sales trends and strategic initiatives aimed at driving growth.

These recent developments highlight the company’s proactive steps in financial management and strategic planning, which have drawn attention from multiple analyst firms. Investors will be closely monitoring how these actions impact Bath & Body Works’ financial performance and market position in the coming quarters.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.